West Pharma (WST) Tops Q4 EPS by 40c; Guides

West Pharma (NYSE: WST) reported Q4 EPS of $1.77, $0.40 better than the analyst estimate of $1.37. Revenue for the quarter came in at $708.7 million versus the consensus estimate of $657.17 million.

GUIDANCE:

West Pharma sees FY2023 EPS of $7.25-$7.40, versus the consensus of $7.27. West Pharma sees FY2023 revenue of $2.935-2.96 million, versus the consensus of $2.87 million.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
• MasTec to acquire The Superior Group for about $1.65 billion
• Principal Financial Group to acquire Beam Benefits, a small-business insurer